ArticleNeurology2021
Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Assessment of venous thromboembolism in adult-type diffuse gliomas at a quaternary neuro-oncology center: a retrospective cross-sectional study and systematic review.Neurosurgical review · 2026Pooled it
- Pooled it
- Development and validation of a competing risk nomogram for predicting PICC-related venous thrombosis in patients with gastrointestinal malignancies.Frontiers in oncology · 2026Article
- Venous thromboembolism and secondary outcomes of bleeding and mortality in patients with gliomas: a multicenter cohort study.Frontiers in oncology · 2026Article
- Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro-oncology · 2025Review
- Development and validation of a multi-parameter nomogram for venous thromboembolism in patients undergoing surgery for brain tumors: a retrospective analysis.Neurosurgical review · 2025Article
- Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors.iScience · 2025Article
- Incidence of Venous Thromboembolism in Newly Diagnosed Glioblastoma and Associated Risk Factors: A Retrospective Chart Review.Current oncology (Toronto, Ont.) · 2025Article
- Machine learning-based MRI radiomics predict IL18 expression and overall survival of low-grade glioma patients.NPJ precision oncology · 2025Article
- Glioblastoma Cells Express and Secrete Alternatively Spliced Transcripts of Coagulation Factor X.Biomedicines · 2025Article
- Myocardial infarction due to non-bacterial thrombotic endocarditis in a patient with oligodendroglioma: an unusual presentation and diagnostic challenge-a case report.European heart journal. Case reports · 2025Article
- Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies.Research and practice in thrombosis and haemostasis · 2025Article
- The risk of venous thromboembolism in adult patients with diffuse glioma: a nationwide population-based study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.Neuro-oncology · 2023Article
- The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma.Current oncology (Toronto, Ont.) · 2023Article
- Article
- Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Neuro-oncology · 2023Article
- Oncogenes and cancer associated thrombosis: what can we learn from single cell genomics about risks and mechanisms?Frontiers in medicine · 2023Review
- Venous thromboembolic events in glioblastoma patients: An epidemiological study.European journal of neurology · 2022Article
- Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the incidence of venous thromboembolism (VTE) in lower-grade gliomas (LGGs, WHO grades II-III) and to stratify the risk of VTE by molecular subtype in gliomas grade II-IV, we performed a retrospective review of a large cohort of patients with glioma.
methodsWe performed a retrospective analysis of a cohort of 635 adult patients with glioma with molecular testing seen at the University of Virginia with a diagnosis of diffuse glioma established from January 2005 to August 2017. Estimates of cumulative incidence of VTE were calculated with death as competing risk; significance was determined using the Fine and Gray model.
resultsOf 256 patients with LGG, 81 were isocitrate dehydrogenase (IDH) wild-type; 113 IDH mutant, 1p/19q codeleted; and 62 IDH mutant, 1p/19q intact. With a median follow-up of 17.9 months, the overall cumulative incidence of VTE was 8.2% for grade II (147 patients), 9.2% for grade III (109 patients), and 30.5% for grade IV (334 patients). In grade II-IV patients, absence of an IDH mutation was associated with a threefold increase in VTE risk when compared to IDH-mutant patients (hazard ratio 3.06, 95% confidence interval 2.03-4.64). In patients with glioblastoma, there was no difference in VTE incidence according to O6-methylguanine-DNA methyltransferase (
conclusionPatients with LGG have a higher VTE risk compared to the general population, which is decreased, but not eliminated, in the presence of an IDH mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.